|Awarded On||August 24, 2018|
|Title||Clinical Evaluation of AVID100, a Highly Potent Antibody-Drug Conjugate, Focusing on Cancer Indications With High Unmet Medical Need|
|Program||Product Development Research|
|Award Mechanism||Texas Company Product Development Awards|
|Institution/Organization||Formation Biologics Corporation|
|Principal Investigator/Program Director||Ilia Tikhomirov|
|Cancer Sites||Breast, Head and Neck, Lung and Bronchus|
Formation Biologics is developing an innovative pipeline of anti-cancer biotherapeutics called antibody-drug conjugates (ADCs). These next-generation treatments are designed to kill cancer cells while sparing healthy cells. Formation’s lead ADC product, AVID100, has been extensively studied and has demonstrated excellent safety and efficacy. It efficiently kills cells from many deadly cancer types including breast, ovarian, head and neck, glioma, pancreatic, gastric and lung. AVID100 is now in early clinical trials in San Antonio exhibiting a good safety profile.
Formation seeks CPRIT funding to expand testing of AVID100 in clinical trials allowing us to evaluate the anti-cancer activity of ...